BDX stock forecast, quote, news & analysis

Key Takeaways

• BDX shares climbed roughly 10.5% over the 30 days ending in late October 2026, rising from a closing price of $179.00 on September 30 to $197.88.
• The advance was led by a landmark partnership with the U.S. government, in which BD pledged $19 billion in planned domestic investment, including $3 billion for manufacturing, in exchange for potential relief from future tariffs.
• Positive nine-month AGILITY trial results for the Revello vascular covered stent added clinical momentum to the interventional portfolio.
• Recent quarterly results showed revenue near $5.0 billion (up 4.4%) and adjusted EPS of $3.23 (up 4.9%), with full-year adjusted EPS guidance raised to $12.62–$12.72.
• Over the last quarter, the stock has gained roughly 20%, reflecting a more focused "New BD" portfolio after the Life Sciences separation.
• For deeper analysis, explore BDX Price Targets, Earnings, and Forecast on dedicated research pages.
• Discover curated automated trading strategies on Tickeron's Trending AI Robots page.

Becton, Dickinson and Company (BDX) Company Overview and Market Position

Becton, Dickinson and Company (NYSE: BDX), commonly known as BD, is one of the world's largest pure-play medical technology companies. Headquartered in Franklin Lakes, New Jersey, BD employs more than 60,000 people globally and delivers billions of medical products annually. Following the early-2026 separation of its Life Sciences business, the "New BD" operates across four segments: Medical Essentials, Connected Care, Biopharma Systems, and Interventional. The company's portfolio spans medication delivery, specimen management, infusion and dispensing, advanced patient monitoring, prefillable drug delivery systems, and surgical and interventional devices. Investors follow the stock for its exposure to essential, recurring healthcare demand, its consumables-driven business model, and a long record of consecutive dividend increases.

Becton, Dickinson and Company (BDX) Stock Price Performance: Last 30 Days vs. Quarter

Over the 30 days ending October 30, 2026, BDX advanced from a closing price of $179.00 on September 30 to $197.88, a gain of approximately 10.5%. The move was not entirely linear: shares dipped to about $176.80 on October 2 before the manufacturing announcement on October 6 sparked a rebound, and the stock reached a session high above $200 on October 22 before settling near $198. Over the last quarter, the trend has been even stronger. The stock has risen roughly 20%, climbing from around $165 in late July to near $198 by the end of October, supported by improving execution and a more focused portfolio.

What Drove BDX Stock Price in the Last 30 Days

The most significant catalyst was the October 6 announcement of a partnership with the U.S. government. BD pledged $19 billion in planned domestic investment over several years—including $3 billion for manufacturing facilities—in exchange for potential relief from future Section 232 tariffs. Shares rose about 2.2% to 2.9% on the news. In the same period, BD reported positive nine-month results from the AGILITY trial of its Revello vascular covered stent, reinforcing the peripheral vascular pipeline. On the analyst front, Citi maintained a Buy rating with a $208 price target, while RBC Capital held a Hold rating at $190; Barclays initiated coverage with an Underweight rating and a $165 target, briefly pressuring the stock in early October. BD also named Ferass Abuzaina as Worldwide President of Surgery and confirmed it would report fiscal fourth-quarter results on November 5.

What Drove BDX Stock Performance Over the Last Quarter

The quarterly advance reflects a broader narrative of portfolio focus and improving execution. In its first full quarter as "New BD" following the Life Sciences separation, BD reported revenue of about $5.0 billion, up 4.4%, with adjusted EPS of $3.23, up 4.9%, both ahead of expectations, and raised full-year adjusted EPS guidance to $12.62–$12.72. Growth was led by double-digit gains in biologic drug delivery, including GLP-1-related demand, advanced patient monitoring, and tissue regeneration, while management navigated known headwinds from Alaris, China, and vaccines. Strong free cash flow supported share repurchases, debt reduction, and continued dividend growth, reinforcing investor confidence in the company's capital-allocation framework.

Trending AI Robots

Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots drawn from a platform that offers hundreds of automated strategies trading thousands of tickers. Only top-performing and most relevant bots appear in this section, and the strategies vary widely in approach, timeframe, and performance metrics, allowing users to evaluate options that align with different trading styles and risk tolerances. The page serves as a starting point for those interested in exploring how algorithmic, data-driven approaches are being applied to equities like BDX. Visitors can browse the selection to identify bots that match their objectives.

BDX Stock Forecast Drivers: What Investors Should Watch Next

Investors are likely to focus on several factors in the near term. BD is scheduled to report fiscal fourth-quarter and full-year 2026 results on November 5, 2026, and will provide its fiscal 2027 outlook, with management signaling that the Alaris headwind is expected to fade after 2027. The implementation and financial details of the U.S. manufacturing agreement, along with the final scope and timing of any Section 232 tariffs, will also be closely watched. Additional items include the pace of stabilization in China and vaccines, continued demand in biologic and GLP-1 drug delivery, and broader medtech sector sentiment tied to inflation and interest rates. A December Analyst Day may offer further detail on strategy and new product initiatives.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations